Response to induction therapy of 328 eligible patients, by treatment arm
| . | AD (n = 161) . | ME (n = 167) . | ||
|---|---|---|---|---|
| n . | % . | n . | % . | |
| Complete response | 69 | 43 | 56 | 34 |
| Resistant disease | 55 | 34 | 72 | 43 |
| Died during aplasia | 4 | 2 | 8 | 5 |
| Died within 7 days after treatment | 12 | 7 | 12 | 7 |
| Died without marrow assessment | 9 | 6 | 11 | 7 |
| Not adequately assessed4-150 | 12 | 7 | 8 | 5 |
| . | AD (n = 161) . | ME (n = 167) . | ||
|---|---|---|---|---|
| n . | % . | n . | % . | |
| Complete response | 69 | 43 | 56 | 34 |
| Resistant disease | 55 | 34 | 72 | 43 |
| Died during aplasia | 4 | 2 | 8 | 5 |
| Died within 7 days after treatment | 12 | 7 | 12 | 7 |
| Died without marrow assessment | 9 | 6 | 11 | 7 |
| Not adequately assessed4-150 | 12 | 7 | 8 | 5 |
AD indicates cytarabine/daunorubicin induction; and ME, mitoxantrone/ etoposide induction.
Responses of these 20 patients could not be adequately assessed using the NCI response criteria (see Cheson et al25). Of these patients, 3 (2 AD and 1 ME) died within 40 days of randomization; 14 (8 AD and 6 ME) died between 130 days and 27 months after randomization; and 3 were alive at 22, 41, and 42 months, respectively, after randomization.